Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4KCYU)

• Drug Name: [3H]8-OH-DPAT Drug Info
• Synonyms: 8-OH-Dpat; 78950-78-4; 8-HYDROXY-2-(DI-n-PROPYLAMINO)TETRALIN; 7-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol; 8-Hydroxy-DPAT; CHEMBL56; Ro-31-8220 in solution; CHEBI:73364; 1-Naphthalenol, 7-(dipropylamino)-5,6,7,8-tetrahydro-; S(-)-8-HYDROXY-DPAT HYDROBROMIDE PARTIAL 5-HT1A SECROT; (+/-)-8-HYDROXY-2-DIPROPYL-AMINOTETRALIN; [3H]-8-OH-DPAT; (+/-)-8-Hydroxy-DPAT hydrobromide; [3H]8-OH-DPAT; (+-)-8-OH-DPAT; S(-)-8-OH-DPAT HBr; S(-)-8-Hydroxy-DPAT hydrobromide; dl-8-Hydroxy-2-(dipropylamino)tetralin; GTPL7; 8OH-DPAT

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 1220
  ChEBI ID: CHEBI:73364
  CAS Number: CAS 78950-78-4
  TTD Drug ID: DM4KCYU

Molecule-Related Drug Atlas

Drug(s) Targeting 5-HT 1B receptor (HTR1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[4]
Eletriptan	DMW649X	Migraine	8A80	Approved	[5]
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[5]
Frovatriptan	DM7RE8P	Migraine	8A80	Approved	[5]
Fluphenazine	DMIT8LX	Psychotic disorder	6A20-6A25	Approved	[5]
Naratriptan	DMO50U2	Migraine	8A80	Approved	[6]
Prolixin decanoate	DMMJ1IS	Schizophrenia	6A20	Approved	[5]
Eltoprazine	DMW6C81	Attention deficit hyperactivity disorder	6A05.Z	Phase 3	[7]
NXN-188	DMMBAIH	Migraine	8A80	Phase 2	[8]
[N-methyl-3H(3)]AZ-10419369	DMSCV02	Mood disorder	6A60-6E23	Phase 1	[9]

Drug(s) Targeting 5-HT 1D receptor (HTR1D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[10]
Eletriptan	DMW649X	Migraine	8A80	Approved	[5]
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[5]
Frovatriptan	DM7RE8P	Migraine	8A80	Approved	[5]
Sumatriptan	DMVYXR8	Migraine	8A80	Approved	[11]
Rizatriptan	DMDJMA3	Migraine	8A80	Approved	[12]
Almogran	DM7I64Z	Migraine	8A80	Approved	[13]
Neu-P11	DMIQDFW	Alzheimer disease	8A20	Phase 2	[14]
FKB01MD	DM2O7NM	N. A.	N. A.	Phase 2	[15]
NXN-188	DMMBAIH	Migraine	8A80	Phase 2	[8]

Drug(s) Targeting 5-HT 1A receptor (HTR1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Trazodone	DMK1GBJ	Depression	6A70-6A7Z	Approved	[5]
Buspirone	DMBS632	Anxiety disorder	6B00-6B0Z	Approved	[16]
OPC-34712	DMHG57U	Major depressive disorder	6A70.3	Approved	[17]
Vilazodone	DM4LECQ	Major depressive disorder	6A70.3	Approved	[18]
Flibanserin	DM70DTN	Mood disorder	6A60-6E23	Approved	[19]
Tertatolol	DM2L3D5	Hypertension	BA00-BA04	Approved	[20]
Urapidil	DMD59GI	Hypertension	BA00-BA04	Approved	[21]
Treximet	DMU54QB	Migraine	8A80	Approved	[22]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[23]
Eltoprazine	DMW6C81	Attention deficit hyperactivity disorder	6A05.Z	Phase 3	[7]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 1A receptor (HTR1A)	TTSQIFT	5HT1A_HUMAN	Agonist	[2]
5-HT 1B receptor (HTR1B)	TTK8CXU	5HT1B_HUMAN	Agonist	[3]
5-HT 1D receptor (HTR1D)	TT6MSOK	5HT1D_HUMAN	Agonist	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 31).
• [2] Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. J Med Chem. 2000 Nov 30;43(24):4701-10.
• [3] Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1999 Jun;359(6):447-53.
• [4] Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem. 1996 Nov;67(5):2096-103.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] Triptans in pregnancy. Ther Drug Monit. 2008 Feb;30(1):5-9.
• [7] Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
• [8] Company report (NeurAxon)
• [9] 5-HT1B and other related serotonergic proteins are altered in APPswe mutation. Neurosci Lett. 2015 May 6;594:137-43.
• [10] Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
• [11] Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
• [12] An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210.
• [13] Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75.
• [14] Clinical pipeline report, company report or official report of Neurim Pharmaceuticals.
• [15] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [16] Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
• [17] Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
• [18] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [19] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [20] Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
• [21] Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
• [22] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [23] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)